Armata Pharma Q3 2022 loss widens to $8.6M; cash at $25.4M; SWARM-P.a. study near completion

Armata Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.79

Loss from operations $(8.6)M in Q3 2022 vs $(6.1)M in Q3 2021, driven by higher R&D spending.
Cash and equivalents $25.4M as of Sept 30, 2022, up from $10.3M at Dec 31, 2021; expects $16.3M in MTEC grant funding.
R&D expenses $8.4M, up from $5.6M; G&A expenses $1.6M, down from $1.8M.
SWARM-P.a. Phase 2 MAD cohort enrollment finishing in Q4; top-line data expected early 2023.
AP-SA02 bacteremia study enrolling Phase 1b; regulatory approvals in Australia to accelerate enrollment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Armata Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: revenue $1.3 million, net income $(8.6) million.

Period: the three months ended September 30, 2022
Revenue: $1.3 million
Net income: $(8.6) million
Result: reported results

Exact text from the filing

Third Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.3 million for the three months ended September 30, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $16.3 million in grant funding from MTEC administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program. The Company recognized approximately $1.3 million of revenue in the comparable period in 2021. Research and Development. Research and development expenses for the three months ended September 30, 2022, were approximately $8.4 million as compared to approximately $5.6 million for the comparable period in 2021. The company continues to invest in clinical trial and personnel related expenses associated with its primary development programs. General an

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-116475

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.